amikacin + amphotericin b + gentamicin + vancomycin

This is a combination of four antimicrobial agents—amikacin, amphotericin B, gentamicin, and vancomycin. Each component has a distinct mechanism of action and spectrum of activity: - **Amikacin** is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. It is primarily used for serious infections caused by Gram-negative bacteria, including multidrug-resistant strains[3][5][6]. - **Gentamicin** is also an aminoglycoside with a similar mechanism as amikacin; it targets the 30S ribosomal subunit to inhibit protein synthesis in bacteria. Gentamicin is effective against both Gram-negative and some Gram-positive organisms[4][7]. - **Vancomycin** is a glycopeptide antibiotic that inhibits cell wall synthesis in susceptible bacteria, particularly effective against Gram-positive organisms such as Staphylococcus aureus and Enterococcus species[2][7]. - **Amphotericin B** is a polyene antifungal agent that binds to ergosterol in fungal cell membranes, creating pores that lead to cell death. This combination would provide extremely broad-spectrum coverage against bacteria (both Gram-negative and Gram-positive) as well as fungi. However, concurrent use of these agents—especially multiple aminoglycosides (amikacin plus gentamicin), or combining nephrotoxic drugs like amphotericin B and vancomycin—is strongly discouraged due to high risk for additive nephrotoxicity and ototoxicity[2][5]. Such combinations are not standard clinical practice except possibly in rare salvage or empiric regimens under close monitoring.